Tarek M Mekhail
Overview
Explore the profile of Tarek M Mekhail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldman J, Karlovich C, Sequist L, Melnikova V, Franovic A, Gadgeel S, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-13.
PMID: 35135111
Purpose: Liquid biopsies represent an attractive alternative to tissue biopsies, particularly rebiopsies, in determining patient eligibility for targeted therapies. Clinical utility of urine genotyping, however, has not been explored extensively....
2.
Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu D, Isla D, et al.
Clin Lung Cancer
. 2019 Feb;
20(3):e407-e412.
PMID: 30808583
Background: Afatinib is a selective, irreversible ErbB family blocker that has shown survival benefit in lung squamous-cell carcinoma (SCC) patients. Pembrolizumab, a humanized immunoglobulin G4 monoclonal antibody to the programmed...
3.
Spigel D, Hainsworth J, Shipley D, Mekhail T, Zubkus J, Waterhouse D, et al.
Lung Cancer
. 2018 Mar;
117:38-43.
PMID: 29496254
Purpose: First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCLC. In...
4.
Spigel D, Mekhail T, Waterhouse D, Hadley T, Webb C, Burris 3rd H, et al.
Cancer Invest
. 2017 Aug;
35(8):541-546.
PMID: 28762849
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m IV,...
5.
Yuan C, Ma M, Parker J, Mekhail T
Am J Case Rep
. 2017 Jul;
18:799-804.
PMID: 28713152
BACKGROUND ALK gene rearrangements as oncogenic drivers have been described in many cancers, including inflammatory myofibroblastic sarcoma (IMS). The first-generation ALK inhibitor was limited in its ability to cross the...
6.
Murthy S, Reznik S, Ogwudu U, Farver C, Arrossi A, Batizy L, et al.
Ann Thorac Surg
. 2010 Sep;
90(4):1067-74.
PMID: 20868788
Background: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease. Therefore, this study characterizes cancer recurrence and...
7.
Luszczek W, Cheriyath V, Mekhail T, Borden E
Mol Cancer Ther
. 2010 Aug;
9(8):2309-21.
PMID: 20682643
Because epigenetic inhibitors can reduce cancer cell proliferation, we tested the hypothesis that concurrent inhibition of histone acetylation and DNA methylation could synergistically reduce the viability of small cell lung...
8.
Videtic G, Reddy C, Chao S, Rice T, Adelstein D, Barnett G, et al.
Int J Radiat Oncol Biol Phys
. 2009 Mar;
75(4):1141-7.
PMID: 19327899
Purpose: To explore whether gender and race influence survival in non-small-cell lung cancer (NSCLC) in patients with brain metastases, using our large single-institution brain tumor database and the Radiation Therapy...
9.
Golshayan A, George S, Heng D, Elson P, Wood L, Mekhail T, et al.
J Clin Oncol
. 2008 Dec;
27(2):235-41.
PMID: 19064974
Purpose: Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease that is associated with poor outcomes to chemotherapy or immunotherapy. The utility of vascular endothelial growth factor...
10.
Videtic G, Rice T, Murthy S, Suh J, Saxton J, Adelstein D, et al.
Int J Radiat Oncol Biol Phys
. 2008 Apr;
72(3):702-6.
PMID: 18374513
Purpose: Mediastinoscopy is routinely carried out on the majority of nonmetastatic, non-small-cell lung cancer (NSCLC) patients in our institution. We used the results of mediastinoscopy from a Stage III NSCLC...